OrthoPediatrics (KIDS) Scheduled to Post Quarterly Earnings on Monday

OrthoPediatrics (NASDAQ:KIDS) is scheduled to release its earnings data after the market closes on Monday, May 6th. Analysts expect OrthoPediatrics to post earnings of ($0.42) per share for the quarter. OrthoPediatrics has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. OrthoPediatrics had a negative net margin of 14.10% and a negative return on equity of 5.03%. The business had revenue of $37.61 million for the quarter, compared to analysts’ expectations of $37.59 million. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

OrthoPediatrics Price Performance

Shares of NASDAQ:KIDS opened at $32.83 on Friday. The firm has a market cap of $781.03 million, a price-to-earnings ratio of -35.68 and a beta of 1.16. OrthoPediatrics has a 1 year low of $23.10 and a 1 year high of $48.47. The company has a current ratio of 5.44, a quick ratio of 2.90 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $28.58 and a 200 day simple moving average of $28.90.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on KIDS shares. JMP Securities reaffirmed a “market outperform” rating and set a $50.00 price target on shares of OrthoPediatrics in a research note on Thursday, March 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $37.00 price objective on shares of OrthoPediatrics in a research report on Wednesday, April 10th. Finally, Truist Financial downgraded shares of OrthoPediatrics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $39.00 to $31.00 in a research report on Thursday, January 25th.

Insider Transactions at OrthoPediatrics

In related news, Director Mark C. Throdahl sold 2,433 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $67,126.47. Following the transaction, the director now directly owns 137,857 shares of the company’s stock, valued at approximately $3,803,474.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, General Counsel Daniel J. Gerritzen sold 2,741 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $27.59, for a total transaction of $75,624.19. Following the completion of the sale, the general counsel now directly owns 52,403 shares of the company’s stock, valued at approximately $1,445,798.77. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Mark C. Throdahl sold 2,433 shares of OrthoPediatrics stock in a transaction on Monday, March 11th. The stock was sold at an average price of $27.59, for a total transaction of $67,126.47. Following the completion of the transaction, the director now owns 137,857 shares in the company, valued at approximately $3,803,474.63. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,253 shares of company stock worth $477,375. 31.80% of the stock is owned by corporate insiders.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.